ClinicalTrials.gg
CompletedNCT03524612TAPERUpdated Jan 7, 2025Results posted

A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP

A Phase 2 interventional study of eltrombopag in Immune Thrombocytopenic Purpura (ITP), sponsored by Novartis Pharmaceuticals. Completed at 32 sites in 15 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
6th of 36
105 · median 40
Started
2018
with 2 others
Phase 2
15 of 36
2 open now
Registered
23rd of 36
by date
Lead sponsor
6 of 36
Novartis Pharmaceuticals

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 6th largest by enrollment, is one of 3 that started in 2018, is one of 15 in phase 2, and was the 23rd registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with steroids.

Read the detailed description

Protocol Amendment 01 added a follow-up period of 12 months for patients with sustained response off treatment at month 12 to obtain further data on response duration.

The starting dose was eltrombopag 50 mg daily (25 mg daily for Asian patients and 12.5 mg daily for Japanese patients in Japan). The starting dose for this study was consistent with the dosing guidelines approved for eltrombopag use in ITP. An increase of eltrombopag dose up to 75 mg was allowed for patients who did not respond to standard-dosage treatment and to reduce the risk of bleeding. The rationale for this increased dose was to use the minimal efficacious dosage of eltrombopag in order to achieve a platelet count ≥ 100×10\^9/L and maintain it around 100×10\^9/L (no counts below 70×10\^9/L) for 2 months in order to allow patients to start the eltrombopag tapering and withdrawal process.

Patients who reached a platelet count of >= 100 × 10\^9/L and maintained counts around 100×10\^9/L for 2 months with no platelet count \< 70 × 10\^9/L were eligible for tapering-off and treatment discontinuation, which occurred via 25 mg reduction every 2 weeks up to 25 mg on alternate days for 2 weeks until treatment discontinuation.

Patients who successfully discontinue eltrombopag and maintained platelet count >= 30 × 10\^9/L in the absence of bleeding or use of rescue therapy were followed to month 12. If a relapse (defined as platelet count \<30 × 10\^9/L) occurred during the 12-month treatment period, they were offered a new course of eltrombopag treatment within this timeframe at the appropriate starting dose. If a patient relapsed in the post 12-month follow-up period, no further attempts for tapering and achieving sustained response off treatment were made.

The taper-off scheme followed recommendations within the current established dosing regimen for when to consider dose adjustment.

03

Conditions studied

  • Immune Thrombocytopenic Purpura (ITP)

Keywords

  • Thrombocytopenic
  • Immune
  • Platelets
  • Bleeding
  • ITP
  • eltrombopag
  • ETB115
  • induce sustained response off treatment
  • refractory or relapsed
  • first-line steroids
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed must be obtained prior to participation in the study
  2. Patients ≥ 18 years old
  3. Patients with a confirmed diagnosis of primary ITP, who are not responsive or in relapse after a of therapy ± intravenous immunoglobulin (IVIG) (used as a rescue therapy)
  4. count \< 30×10\^9/L and assessed as needing treatment (per physician's discretion

Exclusion criteria

Exclusion Criteria:

  1. ITP patients previously treated with any ITP therapies, thrombopoietin receptor (TPO-R) agonists for ITP, except / IVIG
  2. Patients who more than one year after the end of first-line full course of steroid therapy
  3. Patients with a diagnosis of secondary thrombocytopenia
  4. Patients who have life threatening bleeding complications per investigator discretion
  5. Patients who had a deep vein thrombosis or arterial thrombosis in the 6 months preceding enrollment
  6. Serum creatinine ≥ 1.5 mg/dL
  7. Total > 1.5 × (ULN)
  8. (AST) > 3.0 × ULN
  9. Alanine transaminase (ALT) > 3.0 × ULN
  10. Patients who are human immune deficiency virus (), virus (HCV), surface antigen (HBsAg) positive
  11. Patients with hepatic impairment ( score > 5)
  12. Patients who have active
  13. Patients with any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining or compliance with the study procedures per investigator discretion
  14. History or current diagnosis of cardiac disease indicating significant risk of safety for Patients participating in the study
  15. Patients with known active or uncontrolled infections not responding to appropriate therapy
  16. Patients with evidence of current alcohol/drug abuse
  17. Women of and sexually active males unwilling to use adequate during the study
  18. Female Patients who are nursing or pregnant (positive serum or urine B-human chorionic gonadotrophin (B-hCG) pregnancy test) at screening or pre-dose on Day 1

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Other
    eltrombopag

    Participants were treated with eltrombopag to induce sustained response off treatment to reach a target platelet count of \>=100×10\^9/L (CR), after 1st line steroids had failed.

    Drug: eltrombopag

Interventions

  • 12.5, 25, 50 and 75 mg tablets for oral use once daily

    Also known as: ETB115

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months

    Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.

    Time frame: Month 12

Secondary outcomes

  1. Median Duration of Sustained Response Off Treatment (SRoT) After Treatment Discontinuation for Participants With Sustained Response Off Treatment

    Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.

    Time frame: From last dose of eltrombopag to month 12

  2. Estimated Median Duration of Sustained Response Off Treatment (SRoT) for Participants With Sustained Response Off Treatment at Month 12 and Who Enter 12 Months Follow-up Period

    Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy. Patients with SRoT until month 12 who entered follow-up and did not relapse by cut-off date/Month 24 were censored at the earliest of discontinuation date/death date/Month 24 platelet assessment date/cutoff date. Patients with SRoT until Month 12 patients who did not enter or do not yet have data in follow-up phase are censored at their Month 12 platelet assessment date.

    Time frame: From last dose of eltrombopag to relapse, assessed up to month 24

  3. Estimated Median Duration of Sustained Response Off Treatment (SRot) for All Patients

    Patients who tapered and discontinued successfully, or did not relapse/die by cutoff date /month 24 were censored at the earliest of discontinuation date/death date/month 24 platelet assessment date/cutoff date.

    Time frame: From last dose of eltrombopag to month 24

  4. Percentage of Participants With Sustained Response Off Treatment Until Month 24

    Sustained response off treatment is defined as reach platelet count ≥ 100×10\^9/L (complete response \[CR\]) and then maintain platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L) AND then taper off the drug until treatment discontinuation while, maintain platelet count ≥ 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy

    Time frame: Month 15, 18, 21 and 24

  5. Percentage of Participants With Early Response Within First Month

    Early response is defined as reaching a platelet count \>= 50×10\^9/L at least once within the first month (month 1) without bleeding events and no rescue therapy.

    Time frame: By 1 month

  6. Percentage of Participants With Recovery Response in Case of Loss of Response During or After Tapering of Eltrombopag Until Month 24

    Recovery response is defined as platelet count \>=30×10\^9/L after eltrombopag is re-introduced, in case of loss of response (\< 30×10\^9/L and/or bleeding event) without bleeding events and no rescue therapy.

    Time frame: Up to month 24

  7. Relative Change From Baseline in Platelet Count Over Time

    Relative change (%) is the absolute change divided by the platelet counts at baseline and multiplied by 100.

    Time frame: Baseline, month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  8. Percentage of Participants Who Maintain Platelet Counts Level Within 12 Months and Every 3 Months Until Month 24

    Platelet counts level is defined as having platelet counts \>=30×10\^9/L without bleeding events and no rescue therapy.

    Time frame: From first time of reaching the level to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  9. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionaire

    The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities over the past 7 days. FACIT-fatigue is scored using a 4-point Likert scale. Items are scored as follows: 4 = Not At All; 3 = A Little Bit; 2 = Somewhat; 1 = Quite A Bit; 0 = Very Much, EXCEPT items #7 and #8 which are reversed scored. Score range from 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life (less fatigue).

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  10. Change From Baseline in Functional Assessment of Cancer Therapy- Thrombocytopenia (FACT-Th6) Questionnaire

    FACT-Th6 instrument is used to measure worry/concern about bleeding and bruising, and the impact of this worry/concern on physical and social activity (Cella 2006). FACT-Th6 is a 6-item subset of the more detailed FACT-Th, which is an 18-item subscale of the validated FACT that specifically measures concerns related to thrombocytopenia in the past 7 days. The FACT-Th6 is scored using a 5-level Likert scale (0=not at all to 4=very much) and is calculated by summing scores for the 6-items; therefore, scores can range from 0-24, with higher scores representing better HRQoL

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  11. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Bodily Pain (BP) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  12. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: General Health (GH) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  13. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Health (MH) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  14. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Functioning (PF) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  15. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Emotional (RE) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  16. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Physical (RP) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  17. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Social Functioning (SF) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  18. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Vitality (VT) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  19. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Component Summary (PCS) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  20. Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Component Summary (MCS) Score

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

    Time frame: Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

  21. Percentage of Participants With Worst Post-baseline Value in Functional Assessment of Cancer Therapy-G (GP5)

    The GP5 is a single question used to assess the overall bothersomeness of treatment side effects. The GP5 is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bothersomeness from treatment side effects.

    Time frame: Baseline to end of treatment visit, assessed up to 12 months for non-responders and up to 24 months for responders

  22. Overall Change of Treatment Satisfaction Using Treatment Satisfaction Questionnaire (TSQM-9)

    The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

    Time frame: Baseline to month 12 (End of Treatment Visit for non-responders) and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders

07

Results

Posted Dec 27, 2023

Participant flow

This study was conducted in 32 investigative sites in 15 countries:1 (Austria), 3 (Brazil), 2 (Chile), 2 (France), 2 (Greece), 2 (Italy), 1 (Japan), 2 (Mexico), 1 (Oman), 2 (Russia), 7 (Spain), 1 (Switzerland), 3 (Turkey), 1 (UK), 2 (USA).

Participant flow — Overall Study
MilestoneEltrombopag
Started105
Completed63
Not completed42
Withdrew: Lack of efficacy10
Withdrew: Physician decision (patient non-compliant)1
Withdrew: Adverse event10
Withdrew: Withdrawal by subject7
Withdrew: Patient decision (patient changed her address)1
Withdrew: Patient decision (personal reasons)1
Withdrew: New therapy for study indication6
Withdrew: Death3
Withdrew: Lost to follow-up2
Withdrew: Protocol violation1

Outcome measures

PrimaryPercentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months

Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months
Percentage of participantsEltrombopag
Percentage of Participants With Sustained Response Off Treatment (SRoT) by 12 Months30.5 (21.9 to 40.2)
Statistical analysis
  • Eltrombopag · Clopper Pearson test · p = <0.0001
SecondaryMedian Duration of Sustained Response Off Treatment (SRoT) After Treatment Discontinuation for Participants With Sustained Response Off Treatment

Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy until month 12.

Time frame:
From last dose of eltrombopag to month 12
Reported as:
Median · Weeks
Median Duration of Sustained Response Off Treatment (SRoT) After Treatment Discontinuation for Participants With Sustained Response Off Treatment
WeeksEltrombopag
Median Duration of Sustained Response Off Treatment (SRoT) After Treatment Discontinuation for Participants With Sustained Response Off Treatment33.3 (4 to 51)
SecondaryEstimated Median Duration of Sustained Response Off Treatment (SRoT) for Participants With Sustained Response Off Treatment at Month 12 and Who Enter 12 Months Follow-up Period

Sustained response off treatment (SRoT) was defined as: reaching platelet count \>= 100×10\^9/L (complete response \[CR\]) and then maintaining platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L), AND then tapering off the drug until treatment discontinuation while maintaining platelet count \>= 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy. Patients with SRoT until month 12 who entered follow-up and did not relapse by cut-off date/Month 24 were censored at the earliest of discontinuation date/death date/Month 24 platelet assessment date/cutoff date. Patients with SRoT until Month 12 patients who did not enter or do not yet have data in follow-up phase are censored at their Month 12 platelet assessment date.

Time frame:
From last dose of eltrombopag to relapse, assessed up to month 24

No measurements were reported for this outcome.

SecondaryEstimated Median Duration of Sustained Response Off Treatment (SRot) for All Patients

Patients who tapered and discontinued successfully, or did not relapse/die by cutoff date /month 24 were censored at the earliest of discontinuation date/death date/month 24 platelet assessment date/cutoff date.

Time frame:
From last dose of eltrombopag to month 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Sustained Response Off Treatment Until Month 24

Sustained response off treatment is defined as reach platelet count ≥ 100×10\^9/L (complete response \[CR\]) and then maintain platelet counts around 100×10\^9/L for 2 months (no counts below 70×10\^9/L) AND then taper off the drug until treatment discontinuation while, maintain platelet count ≥ 30×10\^9/L in the absence of bleeding (no bleeding AEs) or use of any rescue therapy

Time frame:
Month 15, 18, 21 and 24
Reported as:
Count of participants · Participants
Percentage of Participants With Sustained Response Off Treatment Until Month 24
ParticipantsEltrombopag
Month 1521
Month 1818
Month 2114
Month 2415
SecondaryPercentage of Participants With Early Response Within First Month

Early response is defined as reaching a platelet count \>= 50×10\^9/L at least once within the first month (month 1) without bleeding events and no rescue therapy.

Time frame:
By 1 month
Reported as:
Number · Percentage of participants
Percentage of Participants With Early Response Within First Month
Percentage of participantsEltrombopag
Percentage of Participants With Early Response Within First Month76.2 (66.9 to 84.0)
SecondaryPercentage of Participants With Recovery Response in Case of Loss of Response During or After Tapering of Eltrombopag Until Month 24

Recovery response is defined as platelet count \>=30×10\^9/L after eltrombopag is re-introduced, in case of loss of response (\< 30×10\^9/L and/or bleeding event) without bleeding events and no rescue therapy.

Time frame:
Up to month 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Recovery Response in Case of Loss of Response During or After Tapering of Eltrombopag Until Month 24
Percentage of participantsEltrombopag
Participants with loss of response11.4 (6.0 to 19.1)
Participants with recovery response6.7 (2.7 to 13.3)
SecondaryRelative Change From Baseline in Platelet Count Over Time

Relative change (%) is the absolute change divided by the platelet counts at baseline and multiplied by 100.

Time frame:
Baseline, month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Percentage of change
Relative Change From Baseline in Platelet Count Over Time
Percentage of changeEltrombopag
3 Months1384.29 ± 3383.702
6 Months1313.10 ± 3459.616
9 Months1396.68 ± 3238.680
12 Months1464.95 ± 3509.964
15 Months1622.19 ± 3712.156
18 Months1664.90 ± 3718.191
21 Months2527.20 ± 5098.612
24 Months1691.68 ± 3611.977
end of treatment visit1213.91 ± 2952.719
SecondaryPercentage of Participants Who Maintain Platelet Counts Level Within 12 Months and Every 3 Months Until Month 24

Platelet counts level is defined as having platelet counts \>=30×10\^9/L without bleeding events and no rescue therapy.

Time frame:
From first time of reaching the level to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Number · Percentage of participants
Percentage of Participants Who Maintain Platelet Counts Level Within 12 Months and Every 3 Months Until Month 24
Percentage of participantsEltrombopag
maintain platelet counts level from the first time of reaching that level to month 349.5 (39.6 to 59.5)
maintain platelet counts level from the first time of reaching that level to month 638.1 (28.8 to 48.1)
maintain platelet counts level from the first time of reaching that level to month 928.6 (20.2 to 38.2)
maintain platelet counts level from the first time of reaching that level to month 1228.6 (20.2 to 38.2)
maintain platelet counts level from the first time of reaching that level to month 1520.0 (12.8 to 28.9)
maintain platelet counts level from the first time of reaching that level to month 1817.1 (10.5 to 25.7)
maintain platelet counts level from the first time of reaching that level to month 2113.3 (7.5 to 21.4)
maintain platelet counts level from the first time of reaching that level to month 2414.3 (8.2 to 22.5)
maintain platelet counts level from the first time of reaching that level to end of treatment visit31.4 (22.7 to 41.2)
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionaire

The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities over the past 7 days. FACIT-fatigue is scored using a 4-point Likert scale. Items are scored as follows: 4 = Not At All; 3 = A Little Bit; 2 = Somewhat; 1 = Quite A Bit; 0 = Very Much, EXCEPT items #7 and #8 which are reversed scored. Score range from 0-52. A score of less than 30 indicates severe fatigue. The higher the score, the better the quality of life (less fatigue).

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionaire
Unit on a scaleEltrombopag
3 Months5.42 ± 9.700
6 Months6.15 ± 8.779
9 Months6.89 ± 9.291
12 Months7.90 ± 9.064
15 Months7.12 ± 11.720
18 Months8.87 ± 11.644
21 Months8.80 ± 11.112
24 Months8.69 ± 10.635
end of treatment visit5.40 ± 10.116
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy- Thrombocytopenia (FACT-Th6) Questionnaire

FACT-Th6 instrument is used to measure worry/concern about bleeding and bruising, and the impact of this worry/concern on physical and social activity (Cella 2006). FACT-Th6 is a 6-item subset of the more detailed FACT-Th, which is an 18-item subscale of the validated FACT that specifically measures concerns related to thrombocytopenia in the past 7 days. The FACT-Th6 is scored using a 5-level Likert scale (0=not at all to 4=very much) and is calculated by summing scores for the 6-items; therefore, scores can range from 0-24, with higher scores representing better HRQoL

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Functional Assessment of Cancer Therapy- Thrombocytopenia (FACT-Th6) Questionnaire
Unit on a scaleEltrombopag
3 Months3.80 ± 5.130
6 Months4.35 ± 6.312
9 Months5.60 ± 6.114
12 Months5.62 ± 6.505
15 Months5.44 ± 8.949
18 Months7.04 ± 7.654
21 Months7.32 ± 7.351
24 Months7.08 ± 7.048
end of treatment visit4.15 ± 6.631
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Bodily Pain (BP) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Bodily Pain (BP) Score
Unit on a scaleEltrombopag
3 Months7.55 ± 24.199
6 Months2.75 ± 24.636
9 Months3.82 ± 21.507
12 Months7.53 ± 25.547
15 Months1.96 ± 36.697
18 Months13.61 ± 26.662
21 Months3.00 ± 20.967
24 Months9.27 ± 29.090
end of treatment visit5.19 ± 29.460
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: General Health (GH) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: General Health (GH) Score
Unit on a scaleEltrombopag
3 Months4.12 ± 18.894
6 Months5.39 ± 20.646
9 Months7.40 ± 17.990
12 Months7.62 ± 18.420
15 Months11.17 ± 20.470
18 Months14.78 ± 26.801
21 Months14.36 ± 25.541
24 Months13.92 ± 19.577
end of treatment visit3.80 ± 18.122
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Health (MH) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Health (MH) Score
Unit on a scaleEltrombopag
3 Months6.74 ± 15.775
6 Months6.97 ± 18.149
9 Months9.78 ± 15.074
12 Months10.26 ± 16.125
15 Months7.08 ± 22.259
18 Months15.22 ± 22.334
21 Months14.32 ± 20.948
24 Months12.50 ± 17.103
end of treatment visit6.82 ± 17.058
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Functioning (PF) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Functioning (PF) Score
Unit on a scaleEltrombopag
3 Months8.48 ± 23.842
6 Months10.90 ± 26.069
9 Months12.67 ± 28.074
12 Months14.31 ± 28.767
15 Months11.87 ± 37.469
18 Months19.35 ± 33.449
21 Months24.09 ± 31.983
24 Months16.54 ± 35.882
end of treatment visit9.00 ± 29.376
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Emotional (RE) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Emotional (RE) Score
Unit on a scaleEltrombopag
3 Months4.42 ± 22.371
6 Months6.15 ± 23.270
9 Months8.89 ± 22.361
12 Months10.20 ± 23.260
15 Months4.86 ± 27.022
18 Months13.04 ± 26.211
21 Months16.29 ± 25.520
24 Months16.03 ± 20.128
end of treatment visit7.25 ± 22.078
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Physical (RP) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Role Physical (RP) Score
Unit on a scaleEltrombopag
3 Months13.26 ± 22.958
6 Months9.43 ± 27.066
9 Months17.36 ± 24.165
12 Months19.94 ± 29.232
15 Months15.89 ± 37.454
18 Months22.55 ± 32.680
21 Months27.27 ± 33.604
24 Months29.81 ± 32.849
end of treatment visit15.88 ± 33.332
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Social Functioning (SF) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Social Functioning (SF) Score
Unit on a scaleEltrombopag
3 Months6.06 ± 24.143
6 Months7.17 ± 26.951
9 Months10.00 ± 22.863
12 Months16.38 ± 26.408
15 Months14.58 ± 30.986
18 Months26.63 ± 24.514
21 Months20.45 ± 26.318
24 Months25.96 ± 22.617
end of treatment visit11.18 ± 26.236
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Vitality (VT) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Vitality (VT) Score
Unit on a scaleEltrombopag
3 Months7.48 ± 18.418
6 Months6.45 ± 20.696
9 Months12.78 ± 20.982
12 Months14.33 ± 22.398
15 Months8.33 ± 26.237
18 Months12.23 ± 27.918
21 Months17.33 ± 26.087
24 Months11.06 ± 24.705
end of treatment visit8.97 ± 22.503
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Component Summary (PCS) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Physical Component Summary (PCS) Score
Unit on a scaleEltrombopag
3 Months3.46 ± 7.445
6 Months2.72 ± 8.165
9 Months3.92 ± 7.608
12 Months4.85 ± 8.946
15 Months4.37 ± 11.754
18 Months6.77 ± 9.950
21 Months6.65 ± 8.017
24 Months6.63 ± 9.627
end of treatment visit3.30 ± 9.728
SecondaryChange From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Component Summary (MCS) Score

The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (bodily pain (BP), general health (GH), mental health (MH), physical functioning (PF), role emotional (SE), role physical (RP), social role functioning (SF) and vitality (VT)) which can be aggregated to derive a physical-component summary (PCS) score and a mental-component score (MCS). The SF-36 is scored using norm-based scoring procedures: each sub-scale score ranges from 0 to 10, and the composite score ranges from 0 to 100. Higher scores indicative of better HRQoL.

Time frame:
Baseline to month 3, 6, 9, 12 (End of Treatment Visit for non-responders), 15, 18, 21 and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Change From Baseline in Short Form 36 Health Survey (SF-36v2) Questionnaire: Mental Component Summary (MCS) Score
Unit on a scaleEltrombopag
3 Months2.34 ± 8.443
6 Months2.85 ± 9.451
9 Months4.52 ± 7.815
12 Months5.33 ± 8.719
15 Months3.28 ± 11.083
18 Months7.12 ± 11.312
21 Months7.18 ± 11.143
24 Months6.87 ± 9.081
end of treatment visit3.53 ± 9.002
SecondaryPercentage of Participants With Worst Post-baseline Value in Functional Assessment of Cancer Therapy-G (GP5)

The GP5 is a single question used to assess the overall bothersomeness of treatment side effects. The GP5 is scored using a 5-point rating scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; and 4 = very much), where lower scores reflect less bothersomeness from treatment side effects.

Time frame:
Baseline to end of treatment visit, assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Count of participants · Participants
Percentage of Participants With Worst Post-baseline Value in Functional Assessment of Cancer Therapy-G (GP5)
ParticipantsEltrombopag
Rating 051
Rating 115
Rating 210
Rating 32
Rating 45
Missing22
SecondaryOverall Change of Treatment Satisfaction Using Treatment Satisfaction Questionnaire (TSQM-9)

The Treatment Satisfaction Questionnaire for Medication (TSQM-9) is a psychometric measure of a patient's satisfaction with medication. It consists of 3 subscales: effectiveness, convenience and global satisfaction. The scores were computed by adding items for each domain, i.e. 1 to 3 for effectiveness, 4 - 6 for convenience and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) X 3 items = 18 for the effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. A positive change from baseline indicates improvement.

Time frame:
Baseline to month 12 (End of Treatment Visit for non-responders) and 24 (End of Treatment Visit for responders), assessed up to 12 months for non-responders and up to 24 months for responders
Reported as:
Mean · Unit on a scale
Overall Change of Treatment Satisfaction Using Treatment Satisfaction Questionnaire (TSQM-9)
Unit on a scaleEltrombopag
Global Satisfaction change from BL at 12 months17.78 ± 29.201
Global Satisfaction change from BL at 24 months17.69 ± 26.110
Global Satisfaction change from BL at end of treatment visit9.96 ± 33.966
Effectiveness change from BL at 12 months18.82 ± 33.809
Effectiveness change from BL at 24 months17.99 ± 29.913
Effectiveness change from BL at end of treatment visit14.14 ± 36.673
Convenience change from BL at 12 months17.69 ± 30.758
Convenience change from BL at 24 months19.05 ± 25.189
Convenience change from BL at end of treatment visit15.07 ± 30.253
Total score change from BL at 12 months54.29 ± 78.218
Total score change from BL at 24 months54.72 ± 75.463
Total score change from BL at end of treatment visit39.17 ± 86.449
Post-hocAll Collected Deaths

On-treatment deaths were reported from the date of first dose of eltrombopag to 30 days after the date of the last non-zero dose of eltrombopag for patients who discontinued on or before month 12 (i.e., non-responders). For patients ongoing at month 12, the on-treatment period lasted until the cut-off date for the primary analysis (22-Oct-2021; approximately 35 months), as a patient could restart treatment at any time during study. Post-treatment deaths were collected in the post treatment period from 31 days after last dose of study medication until the cut-off date for the primary analysis (22-Oct-2021; approximately 35 months). These are not considered Adverse Events.

Time frame:
On-treatment deaths: Up to approximately 35 months. Post-treatment deaths: Up to approximately 35 months
Reported as:
Count of participants · Participants
All Collected Deaths
ParticipantsEltrombopag
On-treatment deaths3
Post-treatment deaths1
All deaths4

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days for patients who discontinued on or before month 12. For patients ongoing at month 12, the on-treatment period lasted until the cut-off date for the primary analysis (22-Oct-2021), up to a maximum of 35 months).Deaths were collected in the post treatment follow up period from 31 days after last dose of study medication until the cut-off date for the primary analysis (22-Oct-2021).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag (On-Treatment)3/105 (2.9%)21/105 (20%)64/105 (61%)
Eltrombopag (Post-treatment Follow-up)1/102 (1%)——
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventEltrombopag (On-Treatment)Eltrombopag (Post-treatment Follow-up)
ThrombocytopeniaBlood and lymphatic system disorders3/105—
Intentional product misuseInjury, poisoning and procedural complications2/105—
Platelet count decreasedInvestigations2/105—
EpistaxisRespiratory, thoracic and mediastinal disorders2/105—
DiarrhoeaGastrointestinal disorders1/105—
Upper gastrointestinal haemorrhageGastrointestinal disorders1/105—
VomitingGastrointestinal disorders1/105—
Cholecystitis acuteHepatobiliary disorders1/105—
Cavernous sinus thrombosisInfections and infestations1/105—
Diarrhoea infectiousInfections and infestations1/105—
Most frequent other events
Showing 10 of 15
Most frequent other events
EventEltrombopag (On-Treatment)Eltrombopag (Post-treatment Follow-up)
HeadacheNervous system disorders23/105—
ThrombocytopeniaBlood and lymphatic system disorders16/105—
PetechiaeSkin and subcutaneous tissue disorders11/105—
DiarrhoeaGastrointestinal disorders10/105—
Alanine aminotransferase increasedInvestigations9/105—
NauseaGastrointestinal disorders8/105—
AstheniaGeneral disorders8/105—
AnaemiaBlood and lymphatic system disorders7/105—
Abdominal painGastrointestinal disorders7/105—
Blood alkaline phosphatase increasedInvestigations7/105—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Eltrombopag
Mean48.1 ± 19.39
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female64
Male41
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eltrombopag
American Indian or Alaska Native5
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White95
More than one race0
Unknown or Not Reported1
Time since initial diagnosis
Time since initial diagnosis(Days)Eltrombopag
Mean366.37 ± 911.420
08

Study locations

32 sites
  • Hematology Oncology Association of Rockland
    Nyack, New York 10960, United States
  • Case Western Reserve
    Cleveland, Ohio 44106-5000, United States
  • Novartis Investigative Site
    Linz, 4010, Austria
  • Novartis Investigative Site
    Salvador, BA 41253-190, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20211-030, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05319-000, Brazil
  • Novartis Investigative Site
    Temuco, Araucania 4800827, Chile
  • Novartis Investigative Site
    Vina del Mar, Valparaiso 2540364, Chile
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Pessac Cedex, 33604, France
  • Novartis Investigative Site
    Athens, 115 27, Greece
  • Novartis Investigative Site
    Patras, 265 00, Greece
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Trieste, TS 34129, Italy
  • Novartis Investigative Site
    Nagoya, Aichi 466-8650, Japan
  • Novartis Investigative Site
    Guadalajara, Jalisco 44160, Mexico
  • Novartis Investigative Site
    Ciudad de Mexico, 14000, Mexico
  • Novartis Investigative Site
    Muscat, 123, Oman
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 191024, Russian Federation
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Salamanca, Castilla Y Leon 37007, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Madrid, 28222, Spain
  • Novartis Investigative Site
    Murcia, 30008, Spain
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Aydin, 09100, Turkey
  • Novartis Investigative Site
    Edirne, 22030, Turkey
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Oct 2021, 35 months.

Results were first posted in Dec 2023, 2 years 2 months after primary completion. A results delay was requested in Sep 2022.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2018
First posted
May 15, 2018
StartActual
Nov 2, 2018
Primary completionActual
Oct 22, 2021
CompletionActual
Oct 3, 2022
Results delay requested
Sep 22, 2022
Results first posted
Dec 27, 2023
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03524612
Responsible party
Sponsor
First posted
May 15, 2018
Start date
Nov 2, 2018
Primary completion
Oct 22, 2021
Completion
Oct 3, 2022
Results posted
Dec 27, 2023
Last update
Jan 7, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion